CA

CanBas Co.,Ltd.

A clinical-stage biopharmaceutical company developing novel cancer therapeutics.

4575 | T

Overview

Corporate Details

ISIN(s):
JP3244570002
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号

Description

CanBas is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on drug discovery in the field of oncology, including immuno-oncology and treatments targeting the cell cycle. Its pipeline includes CBP501, a calmodulin-modulating peptide that has undergone Phase II clinical trials. CanBas leverages proprietary screening systems and core technologies to develop innovative anti-cancer agents, with a focus on creating treatments with potentially fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-10-04 08:03
確認書
Japanese 8.2 KB
2021-10-04 08:02
訂正有価証券報告書-第22期(令和2年7月1日-令和3年6月30日)
Japanese 411.5 KB
2021-09-28 09:32
訂正有価証券届出書(組込方式)
Japanese 245.2 KB
2021-09-28 08:02
内部統制報告書-第22期(令和2年7月1日-令和3年6月30日)
Japanese 21.8 KB
2021-09-28 08:01
確認書
Japanese 8.2 KB
2021-09-28 08:01
有価証券報告書-第22期(令和2年7月1日-令和3年6月30日)
Japanese 719.3 KB
2021-09-02 08:34
有価証券届出書(組込方式)
Japanese 402.4 KB
2021-05-14 08:22
四半期報告書-第22期第3四半期(令和3年1月1日-令和3年3月31日)
Japanese 141.2 KB
2021-02-12 07:30
四半期報告書-第22期第2四半期(令和2年10月1日-令和2年12月31日)
Japanese 210.4 KB
2020-11-13 07:10
訂正有価証券届出書(組込方式)
Japanese 166.5 KB
2020-11-13 07:09
四半期報告書-第22期第1四半期(令和2年7月1日-令和2年9月30日)
Japanese 151.2 KB
2020-11-05 08:05
有価証券届出書(組込方式)
Japanese 219.2 KB
2020-09-29 09:14
確認書
Japanese 8.1 KB
2020-09-29 09:13
内部統制報告書-第21期(令和1年7月1日-令和2年6月30日)
Japanese 22.0 KB
2020-09-29 09:10
有価証券報告書-第21期(令和1年7月1日-令和2年6月30日)
Japanese 620.2 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CanBas Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT
Adeia Inc. Logo
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires, develops, and deploys health technologies to address major health challenges.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochip diagnostic systems for precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
United States of America
ALGS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.